RHC 80267

Research use only, not for human use.

RHC 80267 is a selective inhibitor of DAGL (IC50 : 4 μM in canine platelets).

RHC 80267 is a selective inhibitor of DAGL (IC50 : 4 μM in canine platelets) .

The potentiation by RHC 80267 of the relaxation to acetylcholine could be caused by the inhibition of cholinesterase: (1) RHC 80267 does not affect the responses to carbachol, the carbamyl derivative of acetylcholine which only differs from acetylcholine by its resistance to hydrolysis by cholinesterase, and (2) the effect of RHC 80267 is mimicked by the inhibitor of cholinesterase neostigmine, RHC 80267 showing no additional effect in the presence of a maximally effective concentration of neostigmine. The determination of the effect of RHC 80267 on the cholinesterase activity of brain homogenate confirmed that RHC 80267 inhibits this enzyme in the same range of concentrations increasing the relaxation to acetylcholine, namely at 1-10 μM.

RHC 80267 (40 μM) enhances contractions induced by U46619 (a thromboxane A2 analog) in human and rat pulmonary arteries (hPAs and rPAs, respectively) and by angiotensin II (ANG II) in rPAs in an endothelium-dependent manner.

U-57908

Chromatin/Epigenetic

COX

COX|phosphatidylcholine|DAGL

——

——

83654-05-1

394.51

C20H34N4O4

>98% (HPLC)

DMSO:25 mg/mL (63.37 mM; Need ultrasonic)

O=C(NCCCCCCNC(=O)O\N=C1/CCCCC1)O\N=C1\CCCCC1

cyclohexylideneamino N-[6-({[(cyclohexylideneamino)oxy]carbonyl}amino)hexyl]carbamate

(-20℃)

With Ice Pack

≥ 2 years